The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting

Mayo Clin Proc. 2021 Sep;96(9):2305-2308. doi: 10.1016/j.mayocp.2020.12.041.

Authors

Jennifer Gill¹, Ameet Sarpatwari², Vinay Prasad³

Affiliations

¹ Department of Epidemiology and Biostatistics, University of California, San Francisco.
² Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
³ Department of Epidemiology and Biostatistics, University of California, San Francisco. Electronic address: https://twitter.com/vprasadmdmph.

PMID: 34481596
DOI: 10.1016/j.mayocp.2020.12.041

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Drug Approval*
Drug Industry / legislation & jurisprudence
Health Promotion
Humans
Rare Diseases / diagnosis
Rare Diseases / drug therapy*